Difference between revisions of "CDX2"
Jump to navigation
Jump to search
| Line 7: | Line 7: | ||
*Intestinal adenocarcinomas +ve. | *Intestinal adenocarcinomas +ve. | ||
**[[Colorectal adenocarcinoma]]. | **[[Colorectal adenocarcinoma]]. | ||
**[[Small bowel]] adenocarcinoma +ve/-ve (~43% +ve in series of 189 cases<ref name=pmid24603585>{{Cite journal | last1 = Jun | first1 = SY. | last2 = Eom | first2 = DW. | last3 = Park | first3 = H. | last4 = Bae | first4 = YK. | last5 = Jang | first5 = KT. | last6 = Yu | first6 = E. | last7 = Hong | first7 = SM. | title = Prognostic significance of CDX2 and mucin expression in small intestinal adenocarcinoma. | journal = Mod Pathol | volume = | issue = | pages = | month = Mar | year = 2014 | doi = 10.1038/modpathol.2014.36 | PMID = 24603585 }}</ref>). | |||
*[[Ovarian mucinous adenocarcinoma]] +ve.<ref name=pmid14668551/> | *[[Ovarian mucinous adenocarcinoma]] +ve.<ref name=pmid14668551/> | ||
Revision as of 14:39, 23 April 2014
CDX2 is a commonly used immunostain.
Normal
- Intestinal epithelium.[1]
Pathology
- Intestinal adenocarcinomas +ve.
- Colorectal adenocarcinoma.
- Small bowel adenocarcinoma +ve/-ve (~43% +ve in series of 189 cases[2]).
- Ovarian mucinous adenocarcinoma +ve.[1]
References
- ↑ 1.0 1.1 Groisman, GM.; Meir, A.; Sabo, E. (Jan 2004). "The value of Cdx2 immunostaining in differentiating primary ovarian carcinomas from colonic carcinomas metastatic to the ovaries.". Int J Gynecol Pathol 23 (1): 52-7. doi:10.1097/01.pgp.0000101141.31270.a0. PMID 14668551.
- ↑ Jun, SY.; Eom, DW.; Park, H.; Bae, YK.; Jang, KT.; Yu, E.; Hong, SM. (Mar 2014). "Prognostic significance of CDX2 and mucin expression in small intestinal adenocarcinoma.". Mod Pathol. doi:10.1038/modpathol.2014.36. PMID 24603585.